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A genome-wide association study in
multiple system atrophy
ABSTRACT
Objective: To identify genetic variants that play a role in the pathogenesis of multiple system atro-
phy (MSA), we undertook a genome-wide association study (GWAS).
Methods: We performed a GWAS with .5 million genotyped and imputed single nucleotide poly-
morphisms (SNPs) in 918 patients with MSA of European ancestry and 3,864 controls. MSA
cases were collected from North American and European centers, one third of which were neuro-
pathologically confirmed.
Results: We found no significant loci after stringent multiple testing correction. A number of re-
gions emerged as potentially interesting for follow-up at p , 1 3 1026, including SNPs in the
genes FBXO47, ELOVL7, EDN1, and MAPT. Contrary to previous reports, we found no associ-
ation of the genes SNCA and COQ2 with MSA.
Conclusions:We present a GWAS in MSA. We have identified several potentially interesting gene
loci, including theMAPT locus, whose significance will have to be evaluated in a larger sample set.
Common genetic variation in SNCA and COQ2 does not seem to be associated with MSA. In the
future, additional samples of well-characterized patients with MSA will need to be collected to
perform a larger MSAGWAS, but this initial study forms the basis for these next steps. Neurology®
2016;87:1591–1598
GLOSSARY
GWAS 5 genome-wide association study; MAF 5 minor allele frequency; MSA 5 multiple system atrophy; OR 5 odds ratio;
PD 5 Parkinson disease; SNP 5 single nucleotide polymorphism.
Multiple system atrophy (MSA) is an adult-onset neurodegenerative disorder of unknown cause.
Clinical features include parkinsonism, cerebellar ataxia, pyramidal signs, and dysautonomia. MSA
typically presents as a sporadic disease, although rare reports of familial occurrences have been
described,1–3 and there is a greater risk of parkinsonian disorders in relatives of patients with MSA.4
The pathogenesis of MSA is largely unknown. Identification of a-synuclein-positive glial
cytoplasmic inclusions as a neuropathologic hallmark provided the first clue that abnormal protein
accumulation is involved in the development of MSA.5 Furthermore, it suggested a link to other
neurodegenerative diseases that are characterized by a-synuclein deposition, commonly referred to
as synucleinopathies. These include Parkinson disease (PD), MSA, dementia with Lewy bodies,
pure autonomic failure, and neurodegeneration with brain iron accumulation type I.6
Additional evidence in support of shared pathogenic mechanisms among synucleinopathies
was suggested by recent genetic findings demonstrating that variants at the SNCA locus, coding
for the deposited a-synuclein protein, are associated with increased risk for PD and MSA.7,8 In
addition, the (MAPT) H1 haplotype has been associated with MSA.7,9 More recently, the
COQ2 gene was reported to harbor mutations in familial MSA cases from Japan.10 However,
follow-up studies in non-Asian ethnic cohorts were unable to replicate this finding.11,12 Thus,
many prior observations require further evaluation.
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To investigate whether common genetic
risk factors play a role in MSA, we performed
a genome-wide association study (GWAS)
including 918 patients with MSA and 3,864
controls.
METHODS Study design. We performed a multicenter
GWAS with patients with MSA of European ancestry and region-
ally matched controls. Collection sites for this study included
brain banks and clinical centers in Germany, Austria, Netherlands,
Denmark, the United Kingdom, Italy, Portugal, Spain, and the
United States (table e-1 at Neurology.org). Since patients were
recruited in different geographic regions across Europe and the
United States, we matched cases with regional controls.
Genotype data of healthy individuals from previous GWAS were
obtained from Germany, the United Kingdom, the United States,
and Italy. The MSA cases were grouped into 4 geographic regions
and each case was matched with 4 controls from the same
geographic region: UK and Irish MSA cases were matched with
UK controls; Northern European MSA cases from Germany,
Netherlands, Belgium, Austria, Denmark, and Sweden were
matched with German controls; Southern European cases from
Italy and Spain were matched with Italian controls; American
MSA cases were matched with American controls. Matching was
carried out using multidimensional scaling based on the first
2-component vectors for each subpopulation, derived from
common variants assayed in both cases and controls (minor
allele frequency [MAF] . 0.05). A flowchart of studied
populations and quality control steps is shown in figure e-1.
Study participants. DNA samples from a total of 1,030 pa-
tients with MSA were collected for this study (details for each
population are shown in table 1, demographics are listed in table
e-2). Patients were clinically diagnosed with possible or probable
MSA (n 5 699) by movement disorders specialists, or patholog-
ically with definite MSA (n 5 331) by neuropathologists accord-
ing to Gilman criteria.13 For controls, we used genotype data from
3,864 previously published neurologically normal individuals from
the United Kingdom (n 5 936 samples), Germany (n 5 944
samples), United States (n 5 794 samples), and Italy (n 5 1,190
samples) (table 1). All controls were genotyped on Illumina Bead-
Chips (Illumina, San Diego, CA, USA). Details about sample col-
lection and genotyping procedures in control cohorts have been
described elsewhere.7,14–16
Standard protocol approvals, registrations, and patient
consents. The appropriate institutional review boards approved
the study, and written informed consent was obtained for each
participant.
Genotyping. Samples from 1,030 MSA cases were genotyped on
1 of 3 Illumina genotyping BeadChips (Human610-Quad v1,
Human660W-Quad v1, or HumanOmniExpress-12 v1). Control
samples were genotyped on the following BeadChips: UK
WTCCC on Illumina Human1.2M-DuoCustom BeadChip; US,
German, and Italian controls on Illumina BeadChips 550K
version 1 chips or version 3.7,14,16 These chip versions have
343,783 unique single nucleotide polymorphisms (SNPs) in
common, and only shared SNPs were used for downstream
analyses.
Statistical analysis. Genotype calling. For each of the 3 geno-
typing platforms, raw data were imported to GenomeStudio
(v2010.1, genotyping module v1.6.3, Illumina) and genotype
calls were reclustered using a no-call threshold of ,0.15.
Quality control. For quality control, we excluded samples
with a genotyping call rate ,95%, duplicate samples, cryptically
related individuals (pi-hat threshold .0.2), individuals in whom
the reported sex did not match the genotypic sex, and individuals
with non-European ancestry as determined by multiple dimen-
sional scaling analysis (samples deviating.6 SDs from the CEU/
TSI population were excluded; see figure e-2). Next, we excluded
SNPs with inaccurate cluster separation (cluster separation score
,0.3), SNPs that were not shared among all 3 genotyping chip
versions, and SNPs with an individual SNP call rate ,95%.
Following this step, we excluded SNPs with missingness by
haplotype or phenotype that exceeded a significance of p value,
0.0001 or a significant deviation from Hardy-Weinberg equi-
librium with a p value , 0.00001. Of the remaining SNPs, only
those with a MAF .0.01 were used for downstream analyses.
Power calculations and heritability analysis. Power calcu-
lations were performed for a GWAS testing 918 cases and 3,864
controls under a log-additive and a recessive model (QUANTO
software v1.2.3). A minor allele frequency .1% and a 2-sided
a 5 5 3 1028 were assumed. Under the log-additive model
(figure e-3A), power analysis for this study indicated greater than
80% power to detect associated loci with an odds ratio greater than
1.8 at risk allele frequencies between 7% and 87%. We recently
also performed a heritability analysis based on our GWAS data
demonstrating that the heritability for MSA due to common
coding variants is estimated to be between 2.1% and 6.7%.17
Genotype imputation. About 4,903,804 SNPs were imputed
based on haplotype reference data from the 1000 Genomes project
(1000genomes.org/; December 2010 version). These data were
derived from studying the genomic sequence of 104 participants of
European ancestry. Imputations were performed for each of the 4
cohorts separately using MACH software as described elsewhere
(version 1.0.16).18,19 SNPs with an R2,0.3 and MAF,0.01 were
excluded from further analysis as imputed genotypes below this
threshold are likely to be of poor quality.
Association tests. Due to the relatively diverse ancestries of
European and US cohorts included in this study, we used princi-
pal component vectors 1 to 10 from a multidimensional scaling
analysis generated in PLINK as covariates to adjust for possible
population substructure in the logistic regression model used
for the GWAS (figure e-4). The genomic inflation factor was
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Table 1 Samples included
Cohorts
No. of
participants
%
Female
Definite/clinically
diagnosed
Cases
United Kingdom 282 36.8 161/121
United States 148 47.6 126/22
Germany/Austria/Netherlands/Denmark 344 52.5 29/315
Italy/Spain/Portugal 256 53.5 15/241
Total 1,030 47.8 331/699
Controls
United Kingdom 936 47.9 NA
United States 794 57.8 NA
Germany 944 46.8 NA
Italy 1,190 54.2 NA
Total 3,864 52.2 NA
Abbreviation: NA 5 not applicable.
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l 5 1.057. For each SNP, p values and odds ratios under the
additive models were calculated using Mach2dat software.18,19
Only SNPs exceeding the conservative Bonferroni threshold for
multiple testing (p , 5 3 1028) were considered genome-wide
significant. We also performed a subanalysis for association in
pathologically confirmed MSA cases (n 5 295 cases after quality
control) vs 3,864 controls. The genomic inflation factor in this
subgroup was l 5 1.024.
SNCA SNP genotyping using a restriction enzyme assay.
SNP rs11931074, located downstream of the SNCA gene, was re-
genotyped using a restriction enzyme assay. Primers were designed to
amplify the SNP and surrounding region. Restriction enzyme Bsr1
(New England Biolabs, Ipswich, MA) was used to cut the PCR
product. The major allele was cut, whereas the minor allele remained
uncut. Disease association was tested with a x2 test.
Analysis of brain tissue quantitative trait loci. For SNPs of
interest, we attempted to infer functional consequences in frontal
cortex and cerebellar tissue samples from neurologically normal
individuals that were assayed for both genome-wide methyla-
tion and expression levels.20 These analyses may shed light on
potential disease mechanisms for follow-up in future studies. We
tested cis associations (any methylation or expression probes 61
Mb from each SNP) in each of the datasets.21
RESULTS Genotyping, imputation, and quality control.
After quality control procedures, the total study con-
sisted of 918 cases and 3,864 controls. Of the MSA
cases, 291 had a pathologically confirmed diagnosis.
Samples were successfully genotyped for 267,998
SNPs and imputed to 4,903,804 SNPs. After removal
of extreme ancestry outliers and using multidimen-
sional scaling component vectors as covariates in
regression models, only mild population stratification
was evident based on genomic inflation factor calcula-
tions (l 5 1.057) (figure e-2).
Association results. Statistical analysis of association
under an additive model was performed in the full
case-control dataset (figure 1) and in the subset of
MSA cases with neuropathologically confirmed
diagnosis. Loci with the lowest p values (,1 3 1026)
in the full dataset and pathology confirmed cases are
shown in tables 2 and e-3, respectively. In the full
dataset, we identified 4 loci for future follow-up in
a larger sample series at a p value ,1 3 1027
including the genes FBXO47, ELOVL7, EDN1, and
MAPT. None of the tested SNPs surpassed the
Bonferroni threshold for multiple testing (p value ,
5 3 1028) in the full dataset or in the subanalysis of
pathologically confirmed cases.
COQ2 in the MSA GWAS data. Recently, homozygous
(or compound heterozygous) mutations in COQ2
were reported in familial cases of MSA in Japan.10
While coding variants were also found at a higher fre-
quency in sporadic MSA compared to controls, this
finding did not replicate outside of Japanese MSA
samples. We investigated theCOQ2 locus for common
variation in our GWAS data. A total of 453 SNPs in
the COQ2 gene and the flanking region 6100 kb
(build 36.3 positions) were tested for association.
The most associated SNP was chr4:84473327 with
a p value of 0.02169, which is far from genome-wide
or even regional Bonferroni-adjusted significance. We
therefore lack evidence that common genetic variation
in the COQ2 locus plays a major role in MSA risk in
the European/Northern American population.
SNCA rs11931074 SNP genotyping. SNP rs11931074 in
the SNCA locus (or rs3822086, which is in close linkage
disequilibrium) has been linked toMSA in several smaller
studies.8,22,23 This SNP is not represented on the Om-
niExpress Bead arrays; hence, it was not genotyped in any
samples run on this array (n 5 703) and consequently
was not in the dataset of genotyped SNPs in common.
Instead, the allele frequency was calculated postimputa-
tion, demonstrating that it was neither significantly asso-
ciated in the entire dataset (p value5 0.4722) nor in the
subgroup of definite MSA cases (p value5 0.4407). We
Figure 1 Manhattan plot showing association results in multiple system atrophy
p Values under the additive association model are log transformed (y-axis) and plotted against the chromosomal position
(x-axis). The dotted line indicates the threshold of potentially interesting single nucleotide polymorphisms.
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decided to regenotype SNP rs11931074 in the MSA
GWAS cohort using a restriction enzyme to exclude
technical or imputation uncertainty (despite a high impu-
tation score of 0.9670). Within the GWAS cohort, 906
MSA samples were available for regenotyping (table 3).
In controls, data for this SNP were available from the
bead array data. The minor allele of SNP rs11931074
was slightly more common in MSA cases vs controls
(8.3% vs 7.3%) but again no significant association
was found with MSA (x2 5 2.6; p value 5 0.27). This
is in concordance with the imputed GWAS finding, but
contradicts previous reports in the literature.8,22,23
Analysis of brain tissue quantitative trait loci in candidate
loci. Twenty-one out of 24 SNPs of interest (p value
, 1 3 1025) passed quality control in the mRNA
expression datasets, and 23 SNPs of interest passed
quality control in the CpG methylation datasets. We
tested multiple probes per SNP in each set of analyses.
A total of 168 unique SNP–probe pairs were tested in
the frontal cortex mRNA expression dataset, 165 pairs
in the cerebellar mRNA expression dataset, and 391
pairs in the frontal cortex and cerebellar CpG methyl-
ation dataset. Associations were tested using linear
regression adjusting for appropriate covariates and re-
sulting p values were adjusted based on the false-
discovery rate correction as previously described.21
After correcting for multiple testing, we found 8
significant associations between SNPs of interest
and either CpG methylation or mRNA expression
Table 2 Summary of loci with a p value below 1E-6
Chromosome Position Marker
Nearest
gene Location Putative function p Value OR Allelesa
Allele
frequency R2
17 34,359,508 rs78523330 FBXO47 Intronic Involved in protein
ubiquitination and degradation
1.84E-07 0.45 A/G 0.96 0.55
5 60,088,977 rs7715147 ELOVL7 Intronic Lipid metabolism 2.87E-07 1.47 C/A 0.74 0.68
6 12,453,679 rs16872704 EDN1 Intergenic Vasoconstrictor 3.82E-07 1.51 A/G 0.84 0.94
17 41,160,977 rs9303521 CRHR1 Intronic G-protein coupled receptor,
activation
of signal transduction pathways
6.78E-07 0.76 T/G 0.51 0.92
MAPTb Intergenic Microtubule binding protein
1 4,023,064 rs12044274 LOC728716 Intergenic Noncoding RNA 3.30E-06 1.48 T/A 0.65 0.47
6 7,161,483 rs1413700 RREB1 Intronic Zinc finger transcription factor 3.43E-06 1.39 G/C 0.79 0.92
2 239,000,140 rs473651 ASB1 Intergenic Testis development 3.54E-06 0.78 C/A 0.62 0.98
17 42,218,292 rs916888 WNT3 Intergenic WNT signaling gene, embryogenesis 3.68E-06 1.35 T/C 0.75 0.96
14 47,000,222 rs78274439 MDGA2 Intronic Possibly involved in cell–cell
interactions
3.73E-06 1.73 A/G 0.85 0.46
20 59,576,381 rs2252187 CDH4 Intronic Calcium-dependent cell adhesion 3.97E-06 0.74 G/A 0.77 0.81
10 100,039,469 rs4919206 LOXL4 Intergenic Biogenesis of connective tissue 4.36E-06 0.73 C/G 0.49 0.58
17 14,628,830 rs62060075 CDRT7 Intergenic Noncoding RNA 4.64E-06 0.60 C/T 0.92 0.61
8 26,005,267 rs4872401 EBF2 Intergenic Transcription factor 4.75E-06 0.38 G/A 0.96 0.33
5 40,890,439 rs1697938 CARD6 UTR Involved in apoptosis 4.75E-06 0.79 T/C 0.54 0.99
16 22,938,761 rs8044188 USP31 Intergenic Unknown 4.84E-06 1.38 G/A 0.79 0.95
9 128,448,334 rs10819190 LMX1B Intronic Transcription factor 5.41E-06 1.32 G/A 0.63 0.82
5 127,863,758 rs892864 FBN2 Intronic Component of connective tissue
microfibrils
5.96E-06 1.62 T/A 0.06 0.81
2 31,430,416 rs115903524 XDH Intronic Purine degradation 6.41E-06 0.51 G/C 0.97 0.83
19 33,413,730 rs11084877 LOC148189 Intergenic Noncoding RNA 6.65E-06 0.76 A/G 0.76 0.96
2 138,023,816 rs10209086 THSD7B Intronic Unknown 6.95E-06 0.78 T/C 0.42 0.98
9 85,989,249 rs2256039 SLC28A3 Intergenic Nucleoside transporter 7.92E-06 0.70 A/C 0.86 0.74
16 85,251,338 rs78765336 FOXL1 Intergenic Unknown 8.46E-06 0.46 G/T 0.97 0.57
7 24,585,776 rs55782418 MPP6 Intronic Tumor suppression and receptor
clustering
9.59E-06 0.58 G/C 0.96 0.90
17 51,515,165 rs79331640 ANKFN1 Intergenic Unknown 9.97E-06 0.45 G/A 0.97 0.54
Abbreviations: OR 5 odds ratio; UTR 5 untranslated region.
Results for association tests in multiple system atrophy cases vs controls are shown.
a First allele refers to effect allele.
bMAPT is not the closest gene in this locus but due to its known role in other neurodegenerative diseases the most likely candidate.
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(table e-4). All of these were located on chromosome 17
and associated with 3 SNPs (rs78523330, rs9303521,
and rs916888) in a region spanning 8 MB. SNP
rs9393521 is located only 174 Kb upstream of MAPT,
a gene previously suggested as a risk gene for MSA, and
it is within a large 900 kb inversion polymorphism sur-
rounding the MAPT locus.
DISCUSSION The contribution of common genetic
factors to disease development has been established
for many neurodegenerative conditions, which are
complex, often sporadic conditions such as PD and
progressive supranuclear palsy. In MSA, the identity
of these contributing genetic factors remains almost
entirely unknown. Here, we describe a GWAS inves-
tigating common genetic markers in 918 MSA cases
and 3,864 controls for disease association.
Although none of the tested SNPs surpassed the
stringent Bonferroni threshold, we identified 4
MSA regions with p values ,1 3 1026: FBXO47,
ELOVL7, EDN1, and MAPT. These loci are most
promising for further follow-up.
Among the most highly associated regions is the
MAPT locus. MAPT is an intriguing candidate as it
has already been implicated in a number of neurode-
generative diseases, particularly in tauopathies such as
progressive supranuclear palsy, frontotemporal degen-
eration, and Alzheimer dementia.24,25 Although tau is
not considered a key protein in MSA neuropathology,
PD—which is also an a-synucleinopathy—has been
found to be consistently associated with common var-
iation in the MAPT locus.7 Furthermore, MSA was
also previously found to be associated with the MAPT
H1 haplotype in a small cohort of American MSA
cases.9 These results, however, will need to be verified
in a larger MSA cohort.
Located on chromosome 6, EDN1 is part of the
endothelin gene family, which functions in the main-
tenance of vascular tone. Studies have demonstrated
the presence of endothelin peptides in nonvascular struc-
tures including epithelial cells, glia, and neurons.26,27
Given the phenotype of autonomic dysfunction or fail-
ure in patients with MSA, one may hypothesize that
such pathophysiology may be associated with variation
in EDN1.
ELOVL7, originating on chromosome 5, is involved
in transferase activity. Chiefly, transferase is a condens-
ing enzyme that acts as a catalyst for the synthesis of
saturated and polyunsaturated very long chain fatty
acids.28,29
FBXO47 has a known association with papillary
renal cell carcinoma.30 Located on chromosome 17,
FBXO47 promotes protein ubiquitination and degra-
dation via phosphorylation, which are critical mech-
anisms in many neurodegenerative diseases.30,31 This
locus could provide an important mechanism to MSA
pathology in light of the oligodendroglial a-synuclein
burden, but requires further study to draw any
conclusions.
Common variation in the COQ2 gene (recently
found to be mutated in familial and sporadic probable
MSA cases in Japan) did not show a significant asso-
ciation in the MSA GWAS data. This suggests that
common genetic variation in this gene does not play
a major role in disease pathogenesis in patients with
MSA of European descent.
We were unable to replicate the previously reported
association of variants at the SNCA.8,22,23 A Korean
study was also unable to reproduce the association
indicating possible differences between populations
or an actual null result.32 The previously associated
SNP rs11931074 has considerable variation in fre-
quency among different populations. The reported risk
allele has a frequency of about 7%–8% in our different
European controls and in the European HapMap
data.33 In contrast, the same allele is much more abun-
dant in Asian and African populations (e.g., 58% in
Japanese and 68% in Yorubans). Our study attempts
to account for both interpopulation and intrapopula-
tion heterogeneity through principal component anal-
ysis, and interpopulation heterogeneity of SNCA is
a plausible explanation for the previous findings.
The quantitative trait analysis data suggest a com-
plex risk locus on chromosome 17. This includes sev-
eral SNPs in the region associated with multiple
expression or methylation effects. Several of these
genes are involved in pathways potentially relevant
to MSA pathology: namely, the ribosylation protein
(ARL17A), the ribosome protein (RPL19), and the
proteasome protein (PSMB3).
The disease pathology of several neurodegenera-
tive disorders illustrates a common theme of disrup-
ted proteasomal protein clearance and degradation.
Notably, PSMB3 may be involved in trinucleotide
repeat expansion—a phenomenon seen in several
Table 3 Results from the SNCA SNP
rs11931074 restriction enzyme assay
Restriction enzyme digest result
MSA samples 906
TT 7
TG 133
GG 740
MAF MSA 0.0835
MAF control 0.0738
x2 2.6
p Value 0.2725
Abbreviations: MAF 5 minor allele frequency, MSA 5 multiple
system atrophy.
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hereditary neurologic disorders (in particular autoso-
mal dominant ataxias)—and it may be driving the tri-
nucleotide expansion process.34 Supporting this
hypothesis, there is considerable clinical overlap
between MSA and several hereditary ataxias.35,36 Sim-
ilarly, ribosomal dysfunction with aberrant protein
synthesis may promote neurodegeneration.37 Interest-
ingly, no alteration in expression of MAPT—the most
obvious candidate gene in the chromosome 17 locus—
was found. All but one associated QTL in MSA were
found in cerebellar tissue (table e-4). Since the cerebel-
lum is among the most disturbed brain regions in
MSA, differences in expression in this region are con-
sistent with an etiologic role in MSA.
There are a number of limitations to this study.
First, although this represents by far the largest collec-
tion of MSA samples to date, the number of MSA
cases is still relatively small for a GWAS. GWAS are
designed to identify disease variants of relatively high
frequency (MAF .1%) in a population operating
under the common disease/common variant hypoth-
esis.38 In PD, most identified risk factors have an odds
ratio (OR) between 0.8 and 1.5.39 Similarly, in Alz-
heimer disease—apart from APOE (OR ;4)—com-
mon genetic risk factors have low ORs ranging from
0.8 to 1.2. In these diseases, successful identification
of significant loci was only feasible with considerably
larger sample sizes than our study. However, with our
current number we can reasonably exclude the exis-
tence of common risk alleles of large effect. A second
limitation is the use of population control cohorts
rather than age-matched controls, which increases
the chance for population heterogeneity. We applied
stringent corrections, including principal components
from multidimensional scaling as covariates in our
statistical model to address this concern. Third, the
misdiagnosis rate of clinically ascertained patients, in
particular those in early disease stages, can be as high
as 38%.40 We addressed this concern by including
a large number of pathology-proven cases (; one-
third of all patients in this study). The inclusion of
pathology-confirmed cases is particularly important
for future follow-up studies in MSA.
Finally, a major challenge is that currently no
additional large cohorts of MSA cases with a similar
genetic background are available. A comparison of
European and non-European cohorts may be infor-
mative with regard to interpopulation heterogeneity.
None of the studied variants were statistically sig-
nificant after appropriate correction for multiple test-
ing. However, we identified 4 promising loci that
could reveal important insight into the disease path-
ways of MSA. Increasing the sample size of our
GWAS will be key to the successful confirmation of
these candidate loci and the identification of other
risk genes.
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